Impact Factor
4.09
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.74
2,537 total citations
h5-index
52
h5 depth signal
Cited share
85.7%
480 of 560
Total citations
2,537
Citation footprint
Metric signal
4.53
External metric anchor
Self-citation
1.8%
46 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,044
China
433
Germany
275
United Kingdom
248
Italy
218
Citing Fields of Research
Neurodegenerative Disorders
868
Neuromuscular Disorders
611
Brain Neurological Disorders
452
Nervous System Disorders
290
Musculoskeletal Disorders
185
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,841
Articles tracked across the journal lifetime
Indexed publication set
560
480 cited publications
Last 12 months
334
27.8 publications/month
Open access share
100.0%
334 OA publications in the last year
Leading citing country
United States
1,044 citing publications
Leading citing field
Neurodegenerative Disorders
868 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v6n1, Jan. 2019-
v1n1, 2014-
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Neuromuscular Disorders
Brain Neurological Disorders
Musculoskeletal Disorders
Vascular Disorders
Issuing & Sponsoring Bodies
issuing body
American Neurological Association
Broad Categories
Neurology
Neurodegenerative Disorders
Neuromuscular Disorders
Brain Neurological Disorders
Vascular Disorders
Musculoskeletal Disorders
MeSH Descriptors
Nervous System Diseases
Nervous System
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/acn3.70524
Open DOI
Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid
Objective: Blood biomarkers are increasingly critical for non‐invasive Alzheimer's Disease (AD) diagnostics and research but typically require on‐site processing. Remote point‐of‐care collection methods could enhance biomarker testing in...
02
DOI 10.1002/acn3.70550
Open DOI
Dysregulated Cholesterol Metabolism, Chronic Inflammation, and Disability in Severe Progressive Multiple Sclerosis
Background: Dysregulated lipid metabolism, which can affect remyelination and neural repair, has not been extensively investigated in progressive multiple sclerosis (PMS). The goal was to examine whether dysregulated cholesterol metaboli...
03
DOI 10.1002/acn3.70555
Open DOI
Stage‐Specific Patterns of Imaging and Non‐Motor Biomarkers in Spinocerebellar Ataxia Type 3
Objective: Advancements in disease‐modifying therapies for spinocerebellar ataxia Type 3 (SCA3) underscore the need for robust biomarkers to monitor disease progression and evaluate treatment efficacy. Although motor phenotypes have been...
04
DOI 10.1002/acn3.70546
Open DOI
Diffusion Basis Spectrum Imaging of Tissue Microstructure and Early Treatment in Multiple Sclerosis
Objective: Conventional MRI cannot resolve the coexisting pathological processes within multiple sclerosis tissue. Diffusion Basis Spectrum Imaging decomposes the diffusion signal into fiber, cell, and hindered ratios indexing axonal int...
05
DOI 10.1002/acn3.70554
Open DOI
Juvenile Huntington Disease With Cerebellar‐Predominant Atrophy Identified by Genome Sequencing
Juvenile Huntington disease accounts for a small fraction of Huntington disease cases and is driven by the largest trinucleotide repeat expansions. We describe a 6‐year‐old boy with progressive global regression, generalized dystonia, an...
06
DOI 10.1002/acn3.70547
Open DOI
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and...
07
DOI 10.1002/acn3.70487
Open DOI
Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
Diabetes‐associated cognitive impairment (DACI) is a common yet underrecognized condition, manifesting along a spectrum from mild cognitive impairment to dementia. DACI encompasses patients who develop vascular dementia (VaD) or Alzheime...
08
DOI 10.1002/acn3.70553
Open DOI
Complementing Engel Classification: Postoperative Scalp EEG as an Objective Indicator in SEEG ‐Guided Radiofrequency Thermocoagulation—A Seizure‐Onset Pattern‐Based Stratified Analysis—
Background: Stereoelectroencephalography‐guided radiofrequency thermocoagulation (SEEG‐RFTC) is a minimally invasive therapy for drug‐resistant focal epilepsy. However, the relationship between specific seizure‐onset patterns (SOPs), par...
09
DOI 10.1002/acn3.70534
Open DOI
Generalized Dystonia With Cervical Predominance in a Patient With a De Novo TCF20 Variant
TCF20 has been implicated in developmental delay and intellectual disability, with dystonia reported less frequently. We describe a woman in her early twenties with childhood‐onset learning difficulties, progressive dysarthria, tremor, a...
10
DOI 10.1002/acn3.70531
Open DOI
Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact
Objective: To examine the relationship of subjective cognitive concerns (SCC) with biomarkers of Alzheimer's disease (AD), neurodegeneration, and Parkinson's disease (PD) and domain‐specific cognitive trajectories among cognitively unimp...
Bibliographical & Catalog Notes
Some articles in v. 2014 published electronically in 2013.
An official journal of the American Neurological Association.